Biohaven Ltd. (BHVN)

$18.82

-0.27 (-1.41%)
Rating:
Recommendation:
Buy
Symbol BHVN
Price $18.82
Beta 0.000
Volume Avg. 1.10M
Market Cap 1.283B
Shares () -
52 Week Range 5.54-20.07
1y Target Est -
DCF Unlevered BHVN DCF ->
DCF Levered BHVN LDCF ->
ROE 291.55% Strong Buy
ROA -376.52% Strong Sell
Operating Margin -
Debt / Equity 35.35% Neutral
P/E -
P/B 13.34 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BHVN news


Dr. Vladimir Coric M.D.
Healthcare
Biotechnology
New York Stock Exchange

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial to treat spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in Sept 2022. The company was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.